{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:54:49Z","timestamp":1773939289452,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.intimp.2024.112174","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T22:55:04Z","timestamp":1714776904000},"page":"112174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report"],"prefix":"10.1016","volume":"134","author":[{"given":"Nan","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qihong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiting","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanhuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2639-8216","authenticated-orcid":false,"given":"Zhi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.intimp.2024.112174_b0005","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.intimp.2024.112174_b0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.intimp.2024.112174_b0015","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221142133","article-title":"CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma","volume":"13","author":"Mohty","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"10.1016\/j.intimp.2024.112174_b0020","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2024.112174_b0025","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"E.G.C.E.a. clinicalguidelines@esmo.org, Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.intimp.2024.112174_b0030","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines(R), Insights: B-Cell Lymphomas, Version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"27","key":"10.1016\/j.intimp.2024.112174_b0035","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study","volume":"30","author":"Friedberg","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.intimp.2024.112174_b0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.intimp.2024.112174_b0045","first-page":"529","volume":"44","author":"A.","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.intimp.2024.112174_b0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.intimp.2024.112174_b0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.intimp.2024.112174_b0060","doi-asserted-by":"crossref","first-page":"1959102","DOI":"10.1080\/2162402X.2021.1959102","article-title":"Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma","volume":"10","author":"Feng","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112174_b0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"31","key":"10.1016\/j.intimp.2024.112174_b0070","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.intimp.2024.112174_b0075","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.intimp.2024.112174_b0080","doi-asserted-by":"crossref","first-page":"e940954","DOI":"10.12659\/AJCR.940954","article-title":"Pseudo-progression of melanoma treated with nivolumab\/ipilimumab: a case report","volume":"24","author":"Cuevas Velazquez","year":"2023","journal-title":"Am J Case Rep"},{"issue":"1","key":"10.1016\/j.intimp.2024.112174_b0085","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/imt-2020-0188","article-title":"Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy","volume":"13","author":"Huang","year":"2021","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.intimp.2024.112174_b0090","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","article-title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients","volume":"28","author":"Sanmamed","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.intimp.2024.112174_b0095","doi-asserted-by":"crossref","first-page":"11785","DOI":"10.3389\/ti.2023.11785","article-title":"New treatment options for refractory\/resistant CMV infection","volume":"36","author":"Walti","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.intimp.2024.112174_b0100","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"issue":"12","key":"10.1016\/j.intimp.2024.112174_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.09.007","article-title":"Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy","volume":"28","author":"Marquez-Algaba","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.intimp.2024.112174_b0110","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1002\/jmv.27257","article-title":"Severe cytomegalovirus disease with encephalitis after CAR-T cell therapy: A rare but potentially fatal complication","volume":"93","author":"Cousin","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.intimp.2024.112174_b0115","doi-asserted-by":"crossref","first-page":"1226148","DOI":"10.3389\/fimmu.2023.1226148","article-title":"Case report: fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.intimp.2024.112174_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2024.112174_b0125","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s12967-022-03729-5","article-title":"Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products","volume":"20","author":"Shao","year":"2022","journal-title":"J Transl Med"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924006921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924006921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T14:02:54Z","timestamp":1735308174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924006921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":25,"alternative-id":["S1567576924006921"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112174","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112174"}}